TABLE 1.
Baseline characteristics at start of cabozantinib treatment
| RCC patients (n = 25) | SGC patients (n = 22) | |
|---|---|---|
| Age (years) | 67 (37‐81) | 57 (49‐72) |
| Gender | ||
| Male | 21 (84) | 10 (45) |
| KPS | ||
| 90‐100 | 7 (28) | 9 (41) |
| 80‐90 | 9 (36) | 1 (4.5) |
| 70‐80 | 8 (32) | 12 (55) |
| 60‐70 | 1 (4) | 0 |
| Histology | ||
| Clear cell | 20 (80) | NA |
| Papillary | 3 (12) | NA |
| Other RCCs | 2 (8) | NA |
| ACC | NA | 16 (72) |
| SDC | NA | 4 (18) |
| Other SGCs | NA | 2 (9) |
| IMDC risk score | ||
| Intermediate | 13 (52) | NA |
| Poor | 12 (48) | NA |
| Prior treatment | ||
| Surgery | 14 (56) a | 18 (82) |
| Postoperative radiotherapy | NA | 18 (82) |
| Palliative radiotherapy | DNC | 10 (45) |
| Adjuvant systemic therapy | NA | 2 (9) |
| Palliative systemic therapy | 25 (100) | 7 (32) |
| Line of systemic therapy (median, range) | 3 (2‐6) | 2 (1‐5) |
| Prior VEGFR‐I | 25 (100) | 1 (5) |
| Prior ICI | 19 (76) | 0 (0) |
| Weight (kg) | 82 (51‐121) | 76 (54‐111) |
| BMI (kg/m2) | 25.5 (17.8‐36.3) | 25.1 (21.4‐39.9) |
| Haemoglobin (μmol/L) | 7.1 (4.8‐8.7) | 8.2 (6.5‐9.7) |
| Leukocytes (109/L) | 7.9 (4.5‐14.2) | 6.7 (4.1‐11.3) |
| Thrombocytes (109/L) | 337 (210‐984) | 270 (131‐454) |
| Neutrophils (109/L) | 5.9 (3.7‐11.5) | 4.6 (2.3‐8.9) |
| Calcium (mmol/L) | 2.41 (2.24‐2.73) | 2.41 (2.24‐2.65) |
| Serum creatinine (μmol/L) | 121 (52‐228) | 64 (46‐108) |
| ALT (IU/L) | 22 (9‐107) | 23 (12‐76) |
| AST (IU/L) | 24 (18‐49) | 27 (14‐68) |
| Albumin (g/L) | 31.5 (20‐38) | 38.0 (28‐42) |
Note: Data are presented as n (%) for categorical variables and median (range) for continuous variables.
Abbreviations: ACC, adenoid cystic carcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DNC, data not collected; ICI, immune checkpoint inhibitor; IMDC, International Metastatic RCC Database Consortium; NA, not applicable; RCC, renal cell carcinoma; SDC, salivary duct carcinoma; SGC, salivary gland cancer; VEGFR‐I, vascular endothelial growth factor inhibitor.
a
Nephrectomy.